OncoMatch/Clinical Trials/NCT05880667
Adaptive Radiation for Abdominopelvic Metastases
Is NCT05880667 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for neoplasm - soft tissue pelvis malignant secondary.
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Exception: Prior radiotherapy to non-target sites is allowed.
Subjects must not have had prior radiotherapy to any target metastatic lesion. Prior radiotherapy to non-target sites is allowed.
Lab requirements
Blood counts
absolute neutrophil count > 1,500/mcl; platelets > 100,000/mcl
Kidney function
creatinine < 1.5x uln or creatinine clearance ≥ 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal
Liver function
total bilirubin < 2 mg/dl; ast/alt (sgot/sgpt) < 5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify